VIOLIN: Vaccine Investigation and Online Information Network

apxIA
Gene Name	apxIA
Sequence Strain (Species/Organism)	Actinobacillus pleuropneumoniae
VO ID	VO_0011019
NCBI Protein GI	312899
Other Database IDs	CDD:308152 CDD:225483 CDD:311996 GOA:P55128 InterPro: IPR001343 InterPro: IPR003995 InterPro: IPR011049 InterPro: IPR013550 InterPro: IPR018504 InterPro: IPR018511 UniProtKB/UniProt: P55128
Taxonomy ID	754346
Gene Strand (Orientation)	?
Protein pI	5.41
Protein Weight	104857.1
Protein Length	1100
Protein Note	RTX N-terminal domain; pfam02382
Protein Sequence	>CAA51548.1 apxIA [Actinobacillus pleuropneumoniae serovar 9] MANSQLDRVKGLIDSLNQHTKSAAKSGAGALKNGLGQVKQAGQKLILYIPKDYQASTGSSLNDLVKAAEA LGIEVHRSEKNGTALAKELFGTTEKLLGFSERGIALFAPQFDKLLNKNQKLSKSLGGSSEALGQRLNKTQ TALSALQSFLGTAIAGMDLDSLLRRRRNGEDVSGSELAKAGVDLAAQLVDNIASATGTVDAFAEQLGKLG NALSNTRLSGLASKLNNLPDLSLAGPGFDAVSGILSVVSASFILSNKDADAGTKAAAGIEISTKILGNIG KAVSQYIIAQRVAAGLSTTAATGGLIGSVVALAISPLSFLNVADKFERAKQLEQYSERFKKFGYEGDSLL ASFYRETGAIEAALTTINSVLSAASAGVGAAATGSLVGAPVAALVSAITGIISGILDASKQAIFERVATK LANKIDEWEKKHGKNYFENGYDARHSAFLEDTFELLSQYNKEYSVERVVAITQQRWDVNIGELAGITRKG SDTKSGKAYVDFFEEGKLLEKEPDRFDKKVFDPLEGKIDLSSINKTTLLKFVTPVFTAGEEIRERKQTGK YEYMTELFVKGKEKWVVTGVQSHNAIYDYTNLIQLAIDKKGEKRQVTIESHLGEKNDRIYLSSGSSIVYA GNGHDVAYYDKTDTGYLTFDGQSAQKAGEYIVTKELKADVKVLKEVVKTQDISVGKRSEKLEYRDYELSP FELGNGIRAKDELHSVEEIIGSNRKDKFFGSRFTDIFHGAKGDDEIYGNDGHDILYGDDGNDVIHGGDGN DHLVGGNGNDRLIGGKGNNFLNGGDGDDELQVFEGQYNVLLGGAGNDILYGSDGTNLFDGGVGNDKIYGG LGKDIYRYSKEYGRHIIIEKGGDDDTLLLSDLSFKDVGFIRIGDDLLVNKRIGGTLYYHEDYNGNALTIK DWFKEGKEGQNNKIEKIVDKDGAYVLSQYLTELTAPGRGINYFNGLEEKLYYGEGYNALPQLRKDIEQII SSTGAFTGDHGKVSVGSGGPLVYNNSANNVANSLSYSLAQAA
Molecule Role	Protective antigen
Molecule Role Annotation	The ApxI antigen is an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p < 0.01) (Shin et al., 2007).
Related Vaccines(s)	A. pleuropneumoniae ApxIa and ApxIIa protein vaccine , A. pleuropneumoniae ApxIA protein vaccine , A. pleuropneumoniae DNA vaccine pcDNA-apxIA/pcDNA-apxIIA , HS93Tox-/pIG-T1K , mixture of Salmonella strains delivering ApxIA, ApxIIA, ApxIIIA and OmpA of A. pleuropneumoniae , rS.C-APP-ApxI/ApxII
References

apxIA